ノースカロライナにおける大腸癌の臨床試験
ノースカロライナ内の拠点で、大腸癌に関する44件の研究が参加者を募集しています。
ノースカロライナ内の都市
公式研究テキスト（英語）
The Vanguard Study: Testing a New Way to Screen for Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Durham VA Medical Center, Durham
被験者募集中健康なボランティア歓迎
45歳〜75歳 · 全性別 · 2026/10/05更新 · NCT06995898A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
- Duke University Medical Center /ID# 279322, Durham
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07525206A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Carolina Cancer Research Center, Wilson
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
- Wake Forest University Health Sciences, Charlotte
被験者募集中
65歳〜82歳 · 全性別 · 2026/10/02更新 · NCT05612347Family Communications After Genetic Testing
- Southeastern Medical Oncology Center-Clinton, Clinton
- CaroMont Regional Medical Center, Gastonia
- Southeastern Medical Oncology Center-Goldsboro, Goldsboro
- 他2件
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2026/10/02更新 · NCT07143487The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Duke University, Durham
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Cabarrus/LCI-Concord, Concord
- East Carolina University, Greenville
- 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT05673148Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- 他6件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #12, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Duke Cancer Center Cary, Cary
- Duke Cancer Center - Investigational Chemotherapy Service, Durham
- Duke Cancer Center, Durham
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07222800Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- Duke Cancer Center, Durham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05482893A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
- University of North Carolina Medical Center /ID# 267786, Chapel Hill
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06820463A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- University of North Carolina at Chapel Hill, Chapel Hill
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06662786Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Duke University Medical Center, Durham
- Duke Cancer Center Raleigh, Raleigh
- Wake Forest University Health Sciences, Winston-Salem
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT05863195A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Local Institution - 0290, Charlotte
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07221357A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Duke University Medical Center, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07213791Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Duke University Medical Center, Durham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06445062Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Duke University School of Medicine, Durham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT05786924A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Messino Cancer Center, Asheville
- The University of North Carolina At Chapel Hill, Chapel Hill
- Oncology Specialists of Charlotte, Charlotte
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT07284849Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- Clinical Study Site, Pinehurst
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT07228832Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
- Duke Cancer Center, Durham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06252649MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- Duke University Medical Center, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/24更新 · NCT06586515A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
- Duke University Medical Center - Duke Cancer Center, Durham
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07235293FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Duke University, Durham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05919264A Study of DM002 in Patients With Advanced Solid Tumors
- Carolina BioOncology Institute, LLC, Huntersville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/07更新 · NCT06751329A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Huntersville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/06更新 · NCT07749586A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
- GSK Investigational Site, Durham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/03更新 · NCT06885034AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- Duke Cancer Center, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/30更新 · NCT07094113Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #131, Raleigh
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/23更新 · NCT06974110A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
- Duke University Hospital, Durham
- Duke University Medical Center, Duke Cancer Center, Durham
- Duke University Medical Center, Durham
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/07/22更新 · NCT05253651Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
- Duke University Medical Center, Durham
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/15更新 · NCT06937177PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill
被験者募集中
18歳以上 · 全性別 · 2026/07/14更新 · NCT06896162A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
- Duke University Medical Center /ID# 279457, Durham
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/10更新 · NCT07023289A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Research Site, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/10更新 · NCT06835569Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- Duke University Medical Center, Durham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/08更新 · NCT03947385Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Duke Cancer Center, Durham
- Carolina BioOncology Institute, Huntersville
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/03更新 · NCT06040541Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
- Cone Health MedCenter Asheboro, Asheboro
- Cone Health Cancer Center at Alamance Regional, Burlington
- Cone Health Cancer Center, Greensboro
- 他3件
被験者募集中第3相健康なボランティア歓迎
18歳以上 · 全性別 · 2026/03/31更新 · NCT07018869Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Atrium Health Stanly/LCI-Albemarle, Albemarle
- Cone Health MedCenter Asheboro, Asheboro
- Cone Health Cancer Center at Alamance Regional, Burlington
- 他21件
被験者募集中観察研究
18歳以上 · 全性別 · 2026/03/17更新 · NCT06418204Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Carolina BioOncology Institute, Huntersville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/02/18更新 · NCT07030257Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
- Duke Cancer Institute, Durham
被験者募集中
18歳〜39歳 · 全性別 · 2026/01/28更新 · NCT06371768ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。